Format

Send to

Choose Destination
Clin Breast Cancer. 2016 Dec;16(6):437-443. doi: 10.1016/j.clbc.2016.06.002. Epub 2016 Jun 15.

Management and Outcomes in Metaplastic Breast Cancer.

Author information

1
Athens Medical School, Athens, Greece.
2
Athens Medical School, Athens, Greece; Oncology Unit, Third Department of Internal Medicine, Athens Medical School, Sotiria General Hospital, Athens, Greece.
3
First Propaedeutic Surgical Department, Athens Medical School, Hippocration General Hospital, Athens, Greece.
4
Athens Medical School, Athens, Greece; Oncology Unit, Third Department of Internal Medicine, Athens Medical School, Sotiria General Hospital, Athens, Greece. Electronic address: fotopoulos.george1@gmail.com.

Abstract

Metaplastic breast cancer (MBC) constitutes a rare clinical entity with special clinicopathologic, immunohistochemical, and molecular features. Resistance to systemic therapies, whether chemotherapy or hormonal therapy, is among its main characteristics, which in turn explains the poor prognosis and renders its management a challenge. Thus, the scope of the present review is to discuss the current therapeutic strategies for MBC in clinical practice and the corresponding outcomes and to suggest possible directions for future research. Potential novel targeted therapies could provide a hope for better outcomes but limited data are available owing to the rarity of MBC. As knowledge accumulates on the pathogenesis and genetic characteristics of MBC, emphasis should be given to the implementation of more targeted treatments, which will allow more efficient and individualized management of the disease.

KEYWORDS:

Chemotherapy; Genetics; MBC; Review; Targeted therapies

PMID:
27431460
DOI:
10.1016/j.clbc.2016.06.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center